Internal Medicine, Infectious Disease · Newark, NJ
NPI
1578906772
Since 2013
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
166 Lyons Ave Fl 2
Newark, NJ, 07112
Phone (732) 937-8939
Groups this clinician bills Medicare through
Medicare paid, 2024
$23K
271 services
Medicare patients, 2024
117
Average age 65
Drug cost, 2024
$3.9M
1,081 prescriptions
Company payments, 2025
$962
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Madhu Suryadevara was code 99232 (hospital e&m - subsequent), 71 times for 34 patients. In total Madhu Suryadevara billed 271 services in 14 codes, and Medicare paid $23K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 71 | 34 | $63.87 | $4,535 |
| 99233 Hospital E&M - Subsequent | Facility | 71 | 31 | $92.91 | $6,596 |
| 99222 Hospital E&M - Initial | Facility | 34 | 32 | $109.92 | $3,737 |
| 99213 Office E&M - Established | Office | 23 | 19 | $55.83 | $1,284 |
| 99214 Office E&M - Established | Office | 19 | 15 | $92.00 | $1,748 |
| 99442 Telephone Services | Office | 15 | 13 | $55.64 | $835 |
By year: 2023 $29K for 344 services; 2024 $23K for 271 services.
Medicare prescription drug claims, 2024
In 2024, the drug Madhu Suryadevara prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 390 prescriptions and refills. In total Madhu Suryadevara wrote 1,081 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 390 | 417 | 72 | $1.6M |
| Juluca Dolutegravir/Rilpivirine | 97 | 99 | 14 | $359K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 80 | 91 | 15 | $431K |
| Tivicay Dolutegravir Sodium | 62 | 62 | Under 11 | $145K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 52 | 54 | Under 11 | $195K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 50 | 50 | Under 11 | $191K |
| Dovato Dolutegravir Sodium/Lamivudine | 43 | 49 | 12 | $150K |
| Cabenuva Cabotegravir/Rilpivirine | 35 | 61 | Under 11 | $253K |
| Amphotericin B Liposome Generic | 32 | 32 | Under 11 | $224K |
| Micafungin Micafungin Sodium | 32 | 32 | Under 11 | $8,535 |
| Pifeltro Doravirine | 25 | 25 | Under 11 | $43K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 20 | 31 | Under 11 | $172 |
| Descovy Emtricitabine/Tenofov Alafenam | 15 | 15 | Under 11 | $33K |
| Atovaquone-Proguanil Hcl Atovaquone/Proguanil Hcl | 14 | 14 | 13 | $705 |
| Levofloxacin Generic | 13 | 13 | 12 | $17.66 |
Brand drugs: 925 claims; generic drugs: 156 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Madhu Suryadevara $962 ($962 in general payments such as food, travel and fees) from 11 companies. The largest payer was ViiV Healthcare Company with $335.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 19 | $335 |
| Gilead Sciences, Inc. GILD | 10 | $300 |
| Merck Sharp & Dohme LLC MRK | 4 | $80.6 |
| Astellas Pharma US Inc 4503.T | 2 | $40.27 |
| Shionogi Inc 4507.T | 2 | $38.29 |
| La Jolla Pharmaceutical Company | 2 | $38.26 |
| Napo Pharmaceuticals Inc | 2 | $36.78 |
| Theratechnologies Inc. THTX | 2 | $35.23 |
| Pfizer Inc. PFE | 1 | $22.98 |
| Melinta Therapeutics, LLC | 1 | $19.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.